{"id":"rimegepant-75mg-orally-disintegrating-tablets-odt","rwe":[],"tags":[],"safety":{"drugInteractions":[{"drug":"Warfarin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"P-glycoprotein inhibitors (e.g., cyclosporine, ketoconazole)","action":"Monitor","effect":"Increased rimegepant exposure"},{"drug":"P-glycoprotein inducers (e.g., rifampin, St. John's Wort)","action":"Monitor","effect":"Decreased rimegepant exposure"},{"drug":"CYP3A4 inhibitors (e.g., ketoconazole, itraconazole)","action":"Monitor","effect":"Increased rimegepant exposure"},{"drug":"CYP3A4 inducers (e.g., rifampin, St. John's Wort)","action":"Monitor","effect":"Decreased rimegepant exposure"},{"drug":"Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole)","action":"Avoid","effect":"Increased risk of adverse reactions"},{"drug":"Strong CYP3A4 inducers (e.g., rifampin, St. John's Wort)","action":"Avoid","effect":"Decreased efficacy"}],"commonSideEffects":[{"effect":"COVID-19","drugRate":"41.7%","organSystem":"Infections and infestations","placeboRate":"","totalAtRisk":240,"totalAffected":100,"trialsReporting":1},{"effect":"Upper respiratory tract infection","drugRate":"11.7%","organSystem":"Infections and infestations","placeboRate":"","totalAtRisk":240,"totalAffected":28,"trialsReporting":1},{"effect":"Hyperuricaemia","drugRate":"7.5%","organSystem":"Metabolism and nutrition disorders","placeboRate":"","totalAtRisk":240,"totalAffected":18,"trialsReporting":1},{"effect":"Nasopharyngitis","drugRate":"7.1%","organSystem":"Infections and infestations","placeboRate":"","totalAtRisk":240,"totalAffected":17,"trialsReporting":1},{"effect":"Hyperlipidaemia","drugRate":"6.7%","organSystem":"Metabolism and nutrition disorders","placeboRate":"","totalAtRisk":240,"totalAffected":16,"trialsReporting":1},{"effect":"Pyrexia","drugRate":"5.4%","organSystem":"General disorders","placeboRate":"","totalAtRisk":240,"totalAffected":13,"trialsReporting":1},{"effect":"Weight increased","drugRate":"4.6%","organSystem":"Investigations","placeboRate":"","totalAtRisk":240,"totalAffected":11,"trialsReporting":1},{"effect":"Oropharyngeal pain","drugRate":"4.2%","organSystem":"Respiratory, thoracic and mediastinal disorders","placeboRate":"","totalAtRisk":240,"totalAffected":10,"trialsReporting":1},{"effect":"Hepatic function abnormal","drugRate":"4.2%","organSystem":"Hepatobiliary disorders","placeboRate":"","totalAtRisk":240,"totalAffected":10,"trialsReporting":1},{"effect":"Weight decreased","drugRate":"3.8%","organSystem":"Investigations","placeboRate":"","totalAtRisk":240,"totalAffected":9,"trialsReporting":1},{"effect":"Cough","drugRate":"3.8%","organSystem":"Respiratory, thoracic and mediastinal disorders","placeboRate":"","totalAtRisk":240,"totalAffected":9,"trialsReporting":1},{"effect":"Sinus arrhythmia","drugRate":"3.8%","organSystem":"Cardiac disorders","placeboRate":"","totalAtRisk":240,"totalAffected":9,"trialsReporting":1},{"effect":"Anaemia","drugRate":"3.8%","organSystem":"Blood and lymphatic system disorders","placeboRate":"","totalAtRisk":240,"totalAffected":9,"trialsReporting":1},{"effect":"Toothache","drugRate":"3.3%","organSystem":"Gastrointestinal disorders","placeboRate":"","totalAtRisk":240,"totalAffected":8,"trialsReporting":1},{"effect":"Urinary tract infection","drugRate":"2.9%","organSystem":"Infections and infestations","placeboRate":"","totalAtRisk":240,"totalAffected":7,"trialsReporting":1},{"effect":"Alanine aminotransferase increased","drugRate":"2.9%","organSystem":"Investigations","placeboRate":"","totalAtRisk":240,"totalAffected":7,"trialsReporting":1},{"effect":"Influenza","drugRate":"2.5%","organSystem":"Infections and infestations","placeboRate":"","totalAtRisk":240,"totalAffected":6,"trialsReporting":1},{"effect":"Pharyngitis","drugRate":"2.5%","organSystem":"Infections and infestations","placeboRate":"","totalAtRisk":240,"totalAffected":6,"trialsReporting":1},{"effect":"Respiratory tract infection","drugRate":"2.5%","organSystem":"Infections and infestations","placeboRate":"","totalAtRisk":240,"totalAffected":6,"trialsReporting":1},{"effect":"Aspartate aminotransferase increased","drugRate":"2.5%","organSystem":"Investigations","placeboRate":"","totalAtRisk":240,"totalAffected":6,"trialsReporting":1},{"effect":"Sinus bradycardia","drugRate":"2.5%","organSystem":"Cardiac disorders","placeboRate":"","totalAtRisk":240,"totalAffected":6,"trialsReporting":1},{"effect":"Insomnia","drugRate":"2.5%","organSystem":"Psychiatric disorders","placeboRate":"","totalAtRisk":240,"totalAffected":6,"trialsReporting":1},{"effect":"Blood creatine phosphokinase increased","drugRate":"2.1%","organSystem":"Investigations","placeboRate":"","totalAtRisk":240,"totalAffected":5,"trialsReporting":1}],"contraindications":["Patients with a history of hypersensitivity reaction to rimegepant, NURTEC ODT, or to any of its components."],"specialPopulations":{"Pregnancy":"7.1.1 Pregnant Women .............................................................................................6","Geriatric use":"7.1.4 Geriatrics..........................................................................................................7","Paediatric use":"7.1.3 Pediatrics..........................................................................................................6","Renal impairment":"7.1.6 Renal Impairment.............................................................................................7","Hepatic impairment":"7.1.5 Hepatic Impairment..........................................................................................7"},"seriousAdverseEvents":[{"event":"Arteriosclerosis coronary artery","detail":"Cardiac disorders. 1 trial(s).","severity":"serious","incidence":"0.4%"},{"event":"Pneumonia","detail":"Infections and infestations. 1 trial(s).","severity":"serious","incidence":"0.4%"},{"event":"Clavicle fracture","detail":"Injury, poisoning and procedural complications. 1 trial(s).","severity":"serious","incidence":"0.4%"},{"event":"Intervertebral disc protrusion","detail":"Musculoskeletal and connective tissue disorders. 1 trial(s).","severity":"serious","incidence":"0.4%"},{"event":"Benign breast neoplasm","detail":"Neoplasms benign, malignant and unspecified (incl cysts and polyps). 1 trial(s).","severity":"serious","incidence":"0.4%"},{"event":"Brain injury","detail":"Nervous system disorders. 1 trial(s).","severity":"serious","incidence":"0.4%"},{"event":"Varicose vein","detail":"Vascular disorders. 1 trial(s).","severity":"serious","incidence":"0.4%"}]},"trials":[],"aliases":[],"company":"Pfizer","patents":[],"pricing":[],"_sources":{"patents":{"url":"","method":"deterministic","source":"FDA Orange Book + Purple Book","rawText":"","confidence":1,"sourceType":"fda_orange_book","retrievedAt":"2026-04-19T22:29:08.882671+00:00"},"aiSummary":{"url":"","method":"ai_extraction","source":"AI Strategic Summary","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"ai_extraction","retrievedAt":"2026-04-19T22:29:16.874031+00:00"},"chemblData":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL2364629/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T22:29:02.117752+00:00"},"trialDetails":{"url":"","method":"deterministic","source":"ClinicalTrials.gov (0 trials with endpoints)","rawText":"","confidence":1,"sourceType":"ctgov_results","retrievedAt":"2026-04-19T22:29:18.035254+00:00"},"publicationCount":{"url":"","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-19T22:29:01.027052+00:00"},"participantFlowData":{"url":"","method":"deterministic","source":"ClinicalTrials.gov participantFlowModule","rawText":"","confidence":1,"sourceType":"ctgov_results","retrievedAt":"2026-04-19T22:29:18.035249+00:00"},"structuredTrialResults":{"url":"","method":"deterministic","source":"ClinicalTrials.gov resultsSection (0 trials)","rawText":"","confidence":1,"sourceType":"ctgov_results","retrievedAt":"2026-04-19T22:29:18.035247+00:00"},"safety.commonSideEffects":{"url":"","method":"deterministic","source":"ClinicalTrials.gov (1 trials)","rawText":"","confidence":1,"sourceType":"ctgov_results","retrievedAt":"2026-04-20T10:50:29.560033+00:00"},"safety.seriousAdverseEvents":{"url":"","method":"deterministic","source":"ClinicalTrials.gov (0 trials)","rawText":"","confidence":1,"sourceType":"ctgov_results","retrievedAt":"2026-04-19T22:29:18.035223+00:00"}},"allNames":"rimegepant 75mg orally disintegrating tablets (odt)","offLabel":[],"timeline":[],"aiSummary":"Rimegepant 75mg Orally Disintegrating Tablets (ODT), developed by Pfizer, holds a niche position in the migraine treatment market, competing against established brands like Sumatriptan, Nurtec ODT, Imitrex, and Rizatriptan. Its competitive advantage lies in its unique mechanism as a calcitonin gene-related peptide receptor antagonist, offering an alternative to traditional triptans. A key risk is the lack of ongoing clinical trials, which may limit future expansion and innovation. The pipeline outlook remains uncertain due to the absence of new clinical trials and the requirement for a PD-L1 companion diagnostic for several potential indications.","brandName":"Rimegepant 75mg Orally Disintegrating Tablets (ODT)","ecosystem":[],"isGeneric":true,"mechanism":{"target":"calcitonin gene-related peptide receptor","novelty":"first-in-class","modality":"small molecule","drugClass":"calcitonin gene-related peptide receptor antagonist","explanation":"Rimegepant works by blocking the action of calcitonin gene-related peptide (CGRP), a molecule involved in the transmission of pain signals in the brain. This mechanism of action is unique compared to other migraine treatments, which often target other pathways. By blocking CGRP, rimegepant reduces the frequency and severity of migraine attacks.","oneSentence":"Rimegepant is a calcitonin gene-related peptide receptor antagonist.","technicalDetail":"Rimegepant selectively binds to the CGRP receptor, preventing the binding of CGRP and subsequent activation of the receptor. This action reduces the release of pro-inflammatory neuropeptides and neurotransmitters, leading to a decrease in migraine symptoms. The precise molecular mechanism of rimegepant's action is complex and involves multiple signaling pathways."},"_companyIR":{"url":"https://www.pfizer.com/investors","revenueRefs":[],"pipelineRefs":[]},"chemblData":{"prodrug":0,"chemblId":"CHEMBL2364629","maxPhase":"4.0","chirality":1,"parenteral":false,"availability":1,"moleculeType":"Small molecule","withdrawnFlag":false,"naturalProduct":0,"blackBoxWarning":0,"oralBioavailable":true},"commercial":{"annualCostUS":"7000","genericStatus":"Generic — off-patent","peakSalesEstimate":"Not publicly reported"},"fdaRecalls":[],"references":[{"id":1,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=rimegepant-75mg-orally-disintegrating-tablets-odt","fields":["publications"],"source":"PubMed/NCBI"},{"id":2,"url":"https://www.ebi.ac.uk/chembl/","fields":["molecular"],"source":"ChEMBL (EMBL-EBI)"},{"id":3,"url":"https://www.ema.europa.eu/","fields":["regulatoryStatus"],"source":"European Medicines Agency (EMA)"},{"id":4,"url":"https://list.essentialmeds.org/","fields":["regulatoryStatus"],"source":"WHO Essential Medicines List"}],"_tgaChecked":true,"_validation":{"fieldsValidated":2,"lastValidatedAt":"2026-04-20T10:50:30.961261+00:00","fieldsConflicting":0,"overallConfidence":0.95},"_whoChecked":true,"biosimilars":[],"competitors":[{"name":"Sumatriptan","company":"n/a","advantage":"Migraine treatment"},{"name":"Nurtec ODT","company":"n/a","advantage":"Migraine treatment"},{"name":"Imitrex","company":"n/a","advantage":"Migraine treatment"},{"name":"Rizatriptan","company":"n/a","advantage":"Migraine treatment"},{"name":"Botox","company":"n/a","advantage":"Migraine treatment"},{"name":"Ubrelvy (ubrogepant)","company":"n/a","advantage":"CGRP inhibitors"},{"name":"Topiramate","company":"n/a","advantage":"Anticonvulsant and migraine prevention"}],"genericName":"rimegepant-75mg-orally-disintegrating-tablets-odt","indications":{"approved":[{"name":"Acute treatment of migraine attacks with or without aura in adults","regulator":"FDA"}],"offLabel":[],"pipeline":[]},"_mhraChecked":true,"labelChanges":[],"relatedDrugs":[],"trialDetails":[],"_emaApprovals":[{"date":"","name":"Rimegepant 75mg Orally Disintegrating Tablets (ODT)","status":"Authorised","regulator":"EMA"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"molecularData":{"oral":true,"chemblId":"CHEMBL2364629","moleculeType":"Small molecule","molecularWeight":"1221.26"},"_patentsChecked":true,"_warningLetters":[{"date":"03/28/2023","subject":"11/07/2022\tTodos Medical Ltd aka Todos Medical USA Inc\tCenter for Food Safety and Applied Nutrition"},{"date":"03/27/2026","subject":"Feedback form"}],"crossReferences":{"chemblId":"CHEMBL2364629"},"formularyStatus":[],"_offLabelChecked":true,"chemblMechanisms":[{"actionType":"ANTAGONIST","targetChemblId":"CHEMBL3798","mechanismComment":"Therapeutic mechanism not fully elucidated.","mechanismOfAction":"Calcitonin gene-related peptide type 1 receptor antagonist"}],"developmentCodes":[],"ownershipHistory":[],"publicationCount":0,"therapeuticAreas":["Neuroscience"],"biosimilarFilings":[],"recentPublications":[],"_drugWebsiteChecked":true,"participantFlowData":[],"_healthCanadaChecked":true,"companionDiagnostics":[],"_genericFilersChecked":true,"structuredTrialResults":[],"genericManufacturerList":[],"phase":"marketed","status":"approved","companyName":"Pfizer","companyId":"pfizer","modality":"Small molecule","firstApprovalDate":"","enrichmentLevel":5,"visitCount":9,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"EU","regulator":"EMA","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":""},{"country_code":"GB","regulator":"MHRA","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":""}],"pricingByCountry":[{"country_code":"US","currency":"USD","price_amount":"7000.00","price_per":"year","price_type":"annual_list","annual_cost_usd":null,"reimbursement_status":null}],"trialStats":{"total":2,"withResults":1},"validation":{"fieldsValidated":2,"lastValidatedAt":"2026-04-20T10:50:30.961261+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":false,"score":3}}